Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Marcos Oggero"'
Autor:
Natalia Bourguignon, Paola Karp, Carolina Attallah, Daniel A. Chamorro, Marcos Oggero, Ross Booth, Sol Ferrero, Shekhar Bhansali, Maximiliano S. Pérez, Betiana Lerner, Gustavo Helguera
Publikováno v:
Biosensors, Vol 12, Iss 7, p 526 (2022)
To produce innovative biopharmaceuticals, highly flexible, adaptable, robust, and affordable bioprocess platforms for bioreactors are essential. In this article, we describe the development of a large-area microfluidic bioreactor (LM bioreactor) for
Externí odkaz:
https://doaj.org/article/49bc8fe3caa642aaa26d1a24886ac9d2
Autor:
María Fernanda Aguilar, A. Sergio Garay, Carolina Attallah, Daniel E. Rodrigues, Marcos Oggero
Publikováno v:
Molecular Immunology. 151:193-203
The structural and dynamic changes introduced during antibody humanization continue to be a topic open to new contributions. For this reason, the study of structural and functional changes of a murine scFv (mu.scFv) anti-rhIFN-α2b after humanization
Autor:
Viktor A. Zapol’skii, Milagros Bürgi, Marcos Oggero, Mariela Bollati-Fogolín, Dieter E. Kaufmann
Publikováno v:
Arkivoc. 2023
Publikováno v:
Journal of Biotechnology. 327:18-27
Rapid development of effective biotherapeutics has been a concern during the last couple decades. In our work we designed two novel peptide tags, GMOP and mGMOP, derived from the N-terminal region of human granulocyte and macrophage colony stimulatin
Autor:
Marcos Oggero, Natalia Ceaglio, María Jesús Leopold, Eduardo Federico Mufarrege, Marina Etcheverrigaray, Ricardo Kratje, Agustina Gugliotta
Publikováno v:
Pharmaceutical Research. 38:37-50
IFN4N is a glycoengineered version of recombinant human interferon alpha 2 (rhIFN-α2) that was modified to exhibit four N-glycosylation sites. It shows reduced in vitro specific biological activity (SBA) mainly due to R23 mutation by N23. However, i
Publikováno v:
Analytical Biochemistry. 570:56-61
One of the most used formats in inmuno-polymerase chain reaction (IPCR) is known as "Universal" IPCR (signal-generating complexes is based on conjugates of biotinylated DNA, biotinylated IgG and avidin). In the present study, we evaluated the utility
Autor:
Marina Etcheverrigaray, Carolina Attallah, Victoria Lozano, María Carla Rodríguez, Marcos Oggero
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Aim: Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus. An immuno-PCR (iPCR) was developed to quantify low amounts of IFN-α in human plasma followed by a deep analysis of the methodologic robustness throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c98b0e842fca026b95e785c144d505be
https://www.future-science.com/doi/10.4155/bio-2019-0225
https://www.future-science.com/doi/10.4155/bio-2019-0225
Autor:
Eduardo Federico Mufarrege, Sofía Inés Giorgetti, Anne S. De Groot, Frances Terry, Marcos Oggero, Natalia Ceaglio, William J. Martin, Marina Etcheverrigaray
Publikováno v:
Clinical Immunology (Orlando, Fla.)
Human interferon alpha (hIFN-α) administration constitutes the current FDA approved therapy for chronic Hepatitis B and C virus infections. Additionally, hIFN-α treatment efficacy was recently demonstrated in patients with COVID-19. Thus, hIFN-α c
Autor:
Guillermina Forno, Marina Etcheverrigaray, Carolina Attallah, María Fernanda Aguilar, Marcelo M. Brigido, Marcos Oggero, Andrea Queiroz Maranhão
Publikováno v:
Biotechnology letters. 42(8)
The influence of glycosylation on the antigen-neutralizing ability of two potential biotherapeutic anti-human IFN-α2b antibodies composed by murine and humanized single-chain Fv fused to human Fcγ1 (chimeric and humanized scFv-Fc, respectively) was
Autor:
Ricardo Kratje, Marcos Oggero, Milagros Bürgi, Camila Scorticati, Dorella Aquiles, Gabriela I. Aparicio
Publikováno v:
Biotechnology Journal. 16:2000455
Neurological disorders affect millions of people worldwide causing behavior-cognitive disabilities. Nowadays there is no effective treatment for them. Human erythropoietin (hEPO) has been used in clinical tests because of its neurotrophic and cytopro